Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 2, Number 2—April 1996

Dispatch

Improved Serodiagnostic Testing for Lyme Disease: Results of a Multicenter Serologic Evaluation

Robert B. Craven*, Thomas J. Quan*, Raymond E. Bailey*, Raymond Dattwyler†, Raymond W. Ryan‡, Leonard H. Sigal§, Allen C. Steere¶, Bradley Sullivan#, Barbara J.B. Johnson*, David T. Dennis*, and Duane J. Gubler*
Author affiliations: *Centers for Disease Control and Prevention, Fort Collins, Colorado, USA; †State University of New York at Stony Brook, Stony Brook, New York, USA; ‡University of Connecticut Health Center, Farmington, Connecticut, USA; §University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; ¶Tufts/New England Medical Center, Boston, Massachusetts, USA; #Marshfield Clinic, Marshfield, Wisconsin, USA

Main Article

Table 2

Test sensitivity of laboratories demonstrating a test specificity of 98%

Sensitivity, % (positive samples/total)
Clinical Manifestations
Laboratory 1
Laboratory 2
Laboratory 3
Erythema migrans, all 59 (55/94) 60 (56/94) 66 (62/94)
    Acute phasea 65 (11/17) 65 (11/17) 76 (13/17)
    Convalescent phaseb 57 (44/77) 58 (45/77) 64 (49/77)
Carditis 100 (2/2) 100 (2/2) 100 (2/2)
Lyme arthritisc 89 (58/65) 95 (62/65) 92 (60/65)
Neurologic, all 85 (28/33) 88 (29/33) 91 (30/33)
    Early 63 (5/8) 63 (5/8) 75 (6/8)
    Late 91 (10/11) 100 (11/11) 91 (10/11)
    Late and arthritis
93 (13/14)
93 (13/14)
100 (14/14)
Total 74 (143/194) 77 (149/194) 79 (154/194)

a <=30 days from onset of erythema migrans to blood collection.
b > 30 days from onset of erythema migrans to blood collection.
c Without neurologic signs or symptoms.

Main Article

TOP